Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.53 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.51 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.46 |
| ▸ | EBP | Q15125 | 8/20 | 0.42 |
| ▸ | SLC39A7 | Q92504 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8226037 | 0.89 | OPRL1 (0.66) | OPRL1OPRM1OPRK1PDE7APLD1 | |
| SCHEMBL8222333 | 0.88 | OPRL1 (0.68) | OPRL1OPRM1OPRK1PDE7APLD1 | |
| SCHEMBL13314936 | 0.82 | PDE7A (0.55) | OPRL1OPRM1OPRK1PDE7APLD1 | |
| SCHEMBL17779014 | 0.81 | HRH3 (0.46) | OPRL1OPRM1OPRK1EBPSIGMAR1 | |
| SCHEMBL13314896 | 0.79 | OPRL1 (0.53) | OPRL1OPRM1OPRK1PLD1EBP | |
| SCHEMBL13314937 | 0.76 | PDE7A (0.48) | OPRL1OPRM1OPRK1PDE7APLD1 | |
| SCHEMBL12935322 | 0.76 | HRH3 (0.44) | OPRL1OPRM1OPRK1EBPSIGMAR1 | |
| SCHEMBL13052383 | 0.75 | PDE7A (0.58) | OPRL1OPRM1OPRK1PDE7APLD1 | |
| SCHEMBL27048955 | 0.75 | PDE7A (0.58) | PDE7APLD1SLC39A7SIGMAR1 | |
| SCHEMBL25274795 | 0.75 | OPRL1 (0.47) | OPRL1OPRM1OPRK1EBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152176-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152176-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-17 | — | — | US | disclosed |
| US-7696201-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696201-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080176843-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-24 | — | — | US | disclosed |
| US-20080176843-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176843-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | OPRL1 69/4885OPRM1 66/4885OPRK1 114/4885 |
| US-20100152176-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | OPRL1 69/4885OPRM1 66/4885OPRK1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.